Learning about the Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/ metastatic pancreatic duct adenocarcinoma (PDAC)
Uncategorized
1
Posts
1
Posters
0
Views
-
Learning about the Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/ metastatic pancreatic duct adenocarcinoma (PDAC).
Zev A. Wainberg, MD
David Geffen School of Medicine -
I med-mastodon.com shared this topic
